Mariposa is developing an innovative solution to treat the rare skin condition epidermolysis bullosa simplex (EBS). The company is a spin out from Neem Biotech, based in Wales, which has a long history in pharmaceutical research and has extensive capabilities to develop commercially viable solutions for serious healthcare challenges.

Latest News
Jun 25, 2020
Mariposa Therapeutics, a new private biotech company developing a novel topical treatment for patients with epidermolysis bullosa simplex (EBS) was established as a spin out from Neem Biotech, a company focused on the discovery of anti-virulence and anti-bacterial molecules utilising its...
Partners

